Myeloma as a model for the process of metastasis: implications for therapy.

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of multiple myelomatous "omas" throughout the skeleton, indicating that there is continuous trafficking of tumor cells to multiple areas in the bone marrow niches. MM may therefore represent one of the best models to study cell trafficking or cell metastasis. The process of cell metastasis is described as a multistep process, the invasion-metastasis cascade. This involves cell invasion, intravasation into nearby blood vessels, passage into the circulation, followed by homing into predetermined distant tissues, the formation of new foci of micrometastases, and finally the growth of micrometastasis into macroscopic tumors. This review discusses the significant advances that have been discovered in the complex process of invasion-metastasis in epithelial carcinomas and cell trafficking in hematopoietic stem cells and how this process relates to progression in MM. This progression is mediated by clonal intrinsic factors that mediate tumor invasiveness as well as factors present in the tumor microenvironment that are permissive to oncogenic proliferation. Therapeutic agents that target the different steps of cell dissemination and progression are discussed. Despite the significant advances in the treatment of MM, better therapeutic agents that target this metastatic cascade are urgently needed.

[1]  D. Chauhan,et al.  Targeting signalling pathways for the treatment of multiple myeloma , 2005, Expert opinion on therapeutic targets.

[2]  S. Colla,et al.  Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. , 2004, Blood.

[3]  A. Zannettino,et al.  The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma , 2011, Leukemia.

[4]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[5]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[6]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[7]  D. Scadden Circadian rhythms: Stem cells traffic in time , 2008, Nature.

[8]  David W. Rowe,et al.  Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche , 2009, Nature.

[9]  F. Gervasi,et al.  Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment , 2004, Annals of the New York Academy of Sciences.

[10]  O. Sezer Myeloma bone disease , 2005, Hematology.

[11]  P. Richardson,et al.  The malignant clone and the bone-marrow environment. , 2007, Best practice & research. Clinical haematology.

[12]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[13]  M. Dimopoulos,et al.  Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis , 2005, Leukemia & lymphoma.

[14]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[15]  R. Alon,et al.  The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. , 2000, Blood.

[16]  Charles P. Lin,et al.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.

[17]  B. Barlogie,et al.  Myeloma interacts with the bone marrow microenvironment 
to induce osteoclastogenesis and is dependent on osteoclast activity , 2002, British journal of haematology.

[18]  R. Taichman,et al.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.

[19]  A. Régnault,et al.  TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex1 , 2002, The Journal of Immunology.

[20]  Robert A Kyle,et al.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.

[21]  R. Weinberg,et al.  miR-31: A crucial overseer of tumor metastasis and other emerging roles , 2010, Cell cycle.

[22]  R. Carrasco,et al.  Pathogenesis of myeloma. , 2011, Annual review of pathology.

[23]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[24]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[25]  G. Downey,et al.  L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. , 2003, Blood.

[26]  L. Young,et al.  Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model , 2005, Leukemia.

[27]  M. Korpal,et al.  The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.

[28]  Charles P. Lin,et al.  P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. , 2012, Blood.

[29]  Ulrich H. von Andrian,et al.  Stem Cell Trafficking in Tissue Development, Growth, and Disease , 2008, Cell.

[30]  S. Rafii,et al.  Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis , 2004, Nature Medicine.

[31]  H. Döhner,et al.  CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[32]  Y. Tai,et al.  Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma , 2011 .

[33]  P. Croucher,et al.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.

[34]  Bart Barlogie,et al.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.

[35]  Charles P. Lin,et al.  Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. , 2011, Journal of biomedical optics.

[36]  R. Alon,et al.  The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. , 2000, Blood.

[37]  R. Kyle,et al.  Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years , 1996, British journal of haematology.

[38]  E. Ocio,et al.  The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. , 2011, Blood.

[39]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[40]  N. Mechti,et al.  IL-6 regulates CD44 cell surface expression on human myeloma cells , 2004, Leukemia.

[41]  N. Halama,et al.  The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications , 2011, British journal of haematology.

[42]  C. Hart,et al.  Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. , 2010, Blood.

[43]  S. Rajkumar ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management , 2010 .

[44]  R. Alon,et al.  The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. , 1999, The Journal of clinical investigation.

[45]  Hong Chang,et al.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. , 2009, Leukemia research.

[46]  Xin Lu,et al.  Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis , 2010, Clinical Cancer Research.

[47]  T. Martin,et al.  The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and Function* , 2000, The Journal of Biological Chemistry.

[48]  Robert A. Weinberg,et al.  A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .

[49]  Andrés Hidalgo,et al.  Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion , 2004 .

[50]  S. Ergün,et al.  Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells , 2008, Stem Cell Reviews.

[51]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[52]  N. Munshi,et al.  Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. , 2009, Cancer cell.

[53]  T. Komori Regulation of skeletal development by the Runx family of transcription factors , 2005, Journal of cellular biochemistry.

[54]  A. Órfão,et al.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. , 1999, Blood.

[55]  D. Chauhan,et al.  Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.

[56]  P. Selby,et al.  Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry , 2004, Proteomics.

[57]  Hong Zhang,et al.  Circulating endothelial progenitor cells in multiple myeloma: implications and significance. , 2005, Blood.

[58]  T. Lapidot Mechanism of Human Stem Cell Migration and Repopulation of NOD/SCID and B2mnull NOD/SCID Mice , 2001, Annals of the New York Academy of Sciences.

[59]  G. Morgan,et al.  Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial , 2011, The Lancet. Oncology.

[60]  G. Stein,et al.  Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. , 2008, The Journal of clinical investigation.

[61]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[62]  R. Weinberg,et al.  MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis , 2009, Cell cycle.

[63]  R. Kyle,et al.  IgD monoclonal gammopathy with long‐term follow‐up , 1994, British journal of haematology.

[64]  W. Dalton,et al.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.

[65]  I. Fidler,et al.  AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.

[66]  G. Mundy,et al.  A murine model of myeloma that allows genetic manipulation of the host microenvironment , 2009, Disease Models & Mechanisms.

[67]  D. Peeper,et al.  Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB , 2004, Nature.

[68]  N. Clarke,et al.  Parathyroid hormone-related peptide: expression in prostate cancer bone metastases , 2002, Prostate Cancer and Prostatic Diseases.

[69]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[70]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[71]  D. Hedley,et al.  Cancer stem cells, hypoxia and metastasis. , 2009, Seminars in radiation oncology.

[72]  Charles P. Lin,et al.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. , 2007, Blood.

[73]  W. Dupont,et al.  Markers of Epithelial-Mesenchymal Transition and Epithelial Differentiation in Sarcomatoid Carcinoma: Utility in the Differential Diagnosis With Sarcoma , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[74]  K. Podar,et al.  A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. , 2010, Cell cycle.

[75]  H. Döhner,et al.  CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[76]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[77]  R. Fonseca,et al.  Prognostic value of angiogenesis in solitary bone plasmacytoma. , 2003, Blood.

[78]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[79]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[80]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[81]  A. Devys,et al.  [PTHrP and breast cancer]. , 2001, Bulletin du cancer.

[82]  I. Fidler The biology of cancer metastasis. , 2011, Seminars in cancer biology.

[83]  J. Chirgwin,et al.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.

[84]  G. Morgan,et al.  Novel drugs in myeloma: harnessing tumour biology to treat myeloma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[85]  R. Schofield The relationship between the spleen colony-forming cell and the haemopoietic stem cell. , 1978, Blood cells.

[86]  N. Altorki,et al.  Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. , 2009, Biochimica et biophysica acta.

[87]  M. Ratajczak,et al.  Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.

[88]  Andrés Hidalgo,et al.  Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. , 2004, Experimental cell research.

[89]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[90]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[91]  J. Churg,et al.  Multiple myeloma; lesions of the extra-osseous hematopoietic system. , 1950, American journal of clinical pathology.

[92]  D. Scadden,et al.  Stem-cell ecology and stem cells in motion. , 2008, Blood.

[93]  Linheng Li,et al.  The stem cell niches in bone. , 2006, The Journal of clinical investigation.

[94]  C. Mitsiades CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[95]  Laurence Zitvogel,et al.  Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.

[96]  Kou-Juey Wu,et al.  TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development , 2008, Cell cycle.

[97]  Simon C Watkins,et al.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[99]  K. Anderson,et al.  Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. , 2003, Cancer research.

[100]  M. Olivotto,et al.  The role of hypoxia in the maintenance of hematopoietic stem cells. , 1993, Blood.

[101]  S. Orkin,et al.  Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment , 2007, Cell.

[102]  M. Audran,et al.  PTHrP et cancer du sein , 2001 .

[103]  William E. Grizzle,et al.  Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.

[104]  K. Vanderkerken,et al.  The role of the bone marrow microenvironment in multiple myeloma. , 2005, Histology and histopathology.

[105]  G. Roodman Mechanisms of bone metastasis. , 2004, Discovery medicine.

[106]  D. Ribatti,et al.  Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells , 2010, Leukemia.

[107]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[108]  R. Kyle,et al.  Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma , 2010, Current hematologic malignancy reports.

[109]  R. Sanderson,et al.  Heparanase Regulates Levels of Syndecan-1 in the Nucleus , 2009, PloS one.

[110]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[111]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[112]  P. Tassone,et al.  Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. , 2011, Blood.

[113]  J. Body,et al.  A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  D. Scadden,et al.  The stem-cell niche as an entity of action , 2006, Nature.

[115]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  F. Su,et al.  Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.

[117]  A. Nagler,et al.  HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. , 2003, The Journal of clinical investigation.

[118]  F. Prósper,et al.  Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment , 2010 .

[119]  M. Ratajczak,et al.  Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. , 2005, Blood.

[120]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[121]  H. Lokhorst,et al.  Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma , 2012, Leukemia.

[122]  F. Saad Src as a therapeutic target in men with prostate cancer and bone metastases , 2009, BJU international.

[123]  J. Bladé,et al.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[125]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[126]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[127]  Y. Matsuki,et al.  Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.

[128]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[129]  Cameron P Bracken,et al.  MicroRNAs as regulators of epithelial-mesenchymal transition , 2008, Cell cycle.

[130]  B. Pan,et al.  Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor , 1983, Cell.

[131]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[132]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[133]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[134]  G. Raposo,et al.  Exosomes: a common pathway for a specialized function. , 2006, Journal of biochemistry.

[135]  Y. Khotskaya,et al.  Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo* , 2009, The Journal of Biological Chemistry.

[136]  G. Raposo,et al.  Intestinal epithelial cells secrete exosome-like vesicles. , 2001, Gastroenterology.

[137]  R. Kaplan,et al.  Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. , 2006, Breast disease.

[138]  F. Sim,et al.  Solitary plasmacytoma of bone: Mayo Clinic experience. , 1989, International journal of radiation oncology, biology, physics.

[139]  Veronica Huber,et al.  Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles , 2002, The Journal of experimental medicine.

[140]  P. Richardson,et al.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.

[141]  P. Giri,et al.  Exosomes Derived from M. Bovis BCG Infected Macrophages Activate Antigen-Specific CD4+ and CD8+ T Cells In Vitro and In Vivo , 2008, PloS one.

[142]  J. Rak Microparticles in cancer. , 2010, Seminars in thrombosis and hemostasis.

[143]  R. Fonseca,et al.  Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Konstantinos Konstantopoulos,et al.  Cancer cells in transit: the vascular interactions of tumor cells. , 2009, Annual review of biomedical engineering.

[145]  K. Pienta,et al.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. , 2011, The Journal of clinical investigation.

[146]  R. Weinberg,et al.  Chemokine networks and breast cancer metastasis. , 2006, Breast disease.

[147]  Charles P. Lin,et al.  Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. , 2011, Blood.

[148]  K. Anderson,et al.  Characterization of adhesion molecules on human myeloma cell lines. , 1992, Blood.

[149]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[150]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[151]  T. Flores,et al.  P53 deletion may drive the clinical evolution and treatment response in multiple myeloma , 2010, European journal of haematology.

[152]  G. Raposo,et al.  Accumulation of Major Histocompatibility Complex Class Ii Molecules in Mast Cell Secretory Granules and Their Release upon Degranulation Generation of Bmmcs Preparation of B Cells Reagents and Monoclonal Antibodies (mabs) Immunofluorescence Staining and Confocal Microscopy Pulse-chase# Labeling and , 2022 .

[153]  Charles P. Lin,et al.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.